Taisho Pharmaceutical (4581 JP): A Compelling Play on Japan’s Consumer Spending Recovery
Taisho’s mainstay OTC drug business will continue to recover with re-opening of the economy, increasing number of people indulging in outdoor...
406 Views
TOPIX FFW Transition - Big Flows from April to June
Changes to the Topix FFW methodology will result in a turnover of 2.87% & trade of ¥2,285bn from April to June. There is a lot to trade on some...
758 Views
Sawai Pharmaceutical: Big Capacity Expansion Planned Amid Supply Shortages to Drive Market Share
By chalking out a huge capacity expansion plan and new product launches, Sawai is expected to enhance market share in Japan generic drug market,...
220 Views
Biofermin (4517 JP) - Taisho (4581 JP): Merger Is a Done Deal
Taisho Pharma and subsidiary Biofermin (4517) have agreed to merge. The vote looks like a done deal. This is a short-dated rate of return trade.
211 Views
Taisho Pharma Seems the Best Suitor for Takeda’s Japan OTC Business
It was reported by several news media outlets that Blackstone, Bain Capital, CVC Capital Partners and Taisho Pharmaceutical are among the final...
420 Views